Charles Schwab’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.6M | Buy |
336,506
+46,618
| +16% | +$2.53M | ﹤0.01% | 1786 |
|
|
2025
Q4 | $14.2M | Buy |
289,888
+35,754
| +14% | +$1.67M | ﹤0.01% | 1957 |
|
|
2025
Q3 | $11M | Buy |
254,134
+47,469
| +23% | +$1.85M | ﹤0.01% | 2074 |
|
|
2025
Q2 | $7.94M | Buy |
206,665
+35,520
| +21% | +$1.36M | ﹤0.01% | 2128 |
|
|
2025
Q1 | $6.63M | Buy |
171,145
+44,498
| +35% | +$1.63M | ﹤0.01% | 2150 |
|
|
2024
Q4 | $4.28M | Buy |
126,647
+5,044
| +4% | +$182K | ﹤0.01% | 2403 |
|
|
2024
Q3 | $4.97M | Buy |
121,603
+14,687
| +14% | +$601K | ﹤0.01% | 2381 |
|
|
2024
Q2 | $4.12M | Buy |
106,916
+15,224
| +17% | +$640K | ﹤0.01% | 2427 |
|
|
2024
Q1 | $3.93M | Buy |
91,692
+28,181
| +44% | +$1.16M | ﹤0.01% | 2374 |
|
|
2023
Q4 | $2.35M | Buy |
63,511
+18,807
| +42% | +$675K | ﹤0.01% | 2563 |
|
|
2023
Q3 | $1.62M | Buy |
44,704
+19,816
| +80% | +$703K | ﹤0.01% | 2660 |
|
|
2023
Q2 | $887K | Buy |
24,888
+11,366
| +84% | +$408K | ﹤0.01% | 2812 |
|
|
2023
Q1 | $481K | Buy |
13,522
+5,368
| +66% | +$188K | ﹤0.01% | 2964 |
|
|
2022
Q4 | $287K | Buy |
+8,154
| New | +$272K | ﹤0.01% | 3123 |
|
|
2021
Q1 | – | Sell |
-900,000
| Closed | -$41.4M | – | 3502 |
|
|
2020
Q4 | $41.4M | Buy |
900,000
+266,000
| +42% | +$12.2M | 0.02% | 893 |
|
|
2020
Q3 | $29.8M | Buy |
634,000
+10,000
| +2% | +$501K | 0.01% | 948 |
|
|
2020
Q2 | $31.8M | Sell |
624,000
-48,000
| -7% | -$2.46M | 0.02% | 855 |
|
|
2020
Q1 | $31.8M | Buy |
672,000
+29,680
| +5% | +$1.58M | 0.02% | 713 |
|
|
2019
Q4 | $37.7M | Sell |
642,320
-29,680
| -4% | -$1.65M | 0.02% | 799 |
|
|
2019
Q3 | $35.9M | Buy |
672,000
+16,000
| +2% | +$823K | 0.02% | 779 |
|
|
2019
Q2 | $32.8M | Hold |
656,000
| – | – | 0.02% | 810 |
|
|
2019
Q1 | $34.3M | Buy |
+656,000
| New | +$32.8M | 0.02% | 764 |
|
Other funds holding GSK
JEST
